LAL-BR/2001: Study Treatment to Low Risk ALL

• Status: Completed
• Trial end date: 2015-12-01

Summary

The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease

• Phase: Phase 4

Details

• Lead Sponsor: PETHEMA Foundation
• Treatments: 6-Mercaptopurine; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Mercaptopurine; Methotrexate; Prednisone; Vincristine